Get the Stockscreener App
234.78
0.31%
-0.3893
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $234.78, with a volume of 672.51K.
It is down -0.31% in the last 24 hours and up +2.59% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$235.17
Open:
$233.55
24h Volume:
672.51K
Relative Volume:
0.30
Market Cap:
$54.60B
Revenue:
$250.74B
Net Income/Loss:
$1.55B
P/E Ratio:
35.90
EPS:
6.5398
Net Cash Flow:
$4.39B
1W Performance:
-1.16%
1M Performance:
+2.59%
6M Performance:
+3.93%
1Y Performance:
+56.70%
1-Day Range:
$233.55
$238.94
1-Week Range:
$229.33
$258.30
52-Week Range:
$145.87
$258.30
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH vs MCK, COR, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
234.76 | 54.69B | 250.74B | 1.55B | 4.39B | 6.5398 |
MCK
Mckesson Corp
|
857.79 | 101.32B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
312.42 | 59.89B | 328.68B | 2.55B | 1.56B | 13.03 |
HSIC
Henry Schein Inc
|
90.27 | 10.00B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.16 | 1.09B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Baxter’s Interim CFO Anita Zielinski Departs for Cardinal Health - Medical Product Outsourcing
Nippon Life Global Investors Americas Inc. Invests $1.16 Million in Cardinal Health, Inc. $CAH - MarketBeat
Flputnam Investment Management Co. Purchases Shares of 70,728 Cardinal Health, Inc. $CAH - MarketBeat
1ST Source Bank Buys New Holdings in Cardinal Health, Inc. $CAH - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.05 Million in Cardinal Health, Inc. $CAH - MarketBeat
Alberta Investment Management Corp Acquires Shares of 44,600 Cardinal Health, Inc. $CAH - MarketBeat
Cardinal Health Board of Directors Approves Quarterly Dividend - AOL.com
Orca Investment Management LLC Makes New $6.66 Million Investment in Cardinal Health, Inc. $CAH - MarketBeat
ABN AMRO Bank N.V. Buys New Stake in Cardinal Health, Inc. $CAH - MarketBeat
Bridgewater Advisors Inc. Makes New Investment in Cardinal Health, Inc. $CAH - MarketBeat
Summit Global Investments Purchases Shares of 14,684 Cardinal Health, Inc. $CAH - MarketBeat
Stack Financial Management Inc Invests $24.68 Million in Cardinal Health, Inc. $CAH - MarketBeat
Everett Harris & Co. CA Takes $2.14 Million Position in Cardinal Health, Inc. $CAH - MarketBeat
Cardinal Health Inc. stock outperforms competitors on strong trading day - MarketWatch
Cardinal Health CEO details M&A strategy and growth - Yahoo Finance
Reasons to Hold Hinge Health Stock in Your Portfolio for Now - TradingView
Monolithic Power Systems and Las Vegas Sands have been highlighted as Zacks Bull and Bear of the Day - TradingView
Cardinal Health Stock Hits a Record High After Earnings: Is CAH Still a Buy? - TradingView
Cardinal Health Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Wellington Group (CAH) discloses 6.34% beneficial stake in Cardinal Health - Stock Titan
Cardinal Health Stock Loses $912 Million as Recall Searches Test a $63.7 Billion Quarter - TechStock²
JPMorgan Chase & Co. Issues Positive Forecast for Cardinal Health (NYSE:CAH) Stock Price - MarketBeat
Cardinal Health: Q4 Presents Positive Signal For The Company's Long-Term Growth (NYSE:CAH) - Seeking Alpha
Can BWX Technologies' Nuclear Medicine Expansion Boost Growth? - TradingView
Morgan Stanley Sticks to Its Buy Rating for Cardinal Health (CAH) - The Globe and Mail
Evercore ISI Adjusts Cardinal Health PT to $270 From $265, Maintains Outperform Rating - marketscreener.com
JPMorgan Adjusts Cardinal Health Price Target to $260 From $215, Maintains Neutral Rating - marketscreener.com
Deutsche Bank Adjusts Cardinal Health Price Target to $261 From $223, Maintains Hold Rating - marketscreener.com
Citi Keeps Their Buy Rating on Cardinal Health (CAH) - The Globe and Mail
Cardinal Health Is Maintained at Buy by Citigroup - Moomoo
Cardinal Health Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Cardinal Health Says It Now Exclusively Serves Nearly Half The Cell-And-Gene Therapy Market - Sahm
Cardinal Health Analysts Increase Their Forecasts Following Q4 Results - webull.com
Cardinal Health Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - webull.com
Cardinal Health (CAH) Stock Looks About Right On Earnings But Stretched On Broader Checks - Yahoo Finance
Cardinal Health (NYSE:CAH) Given New $280.00 Price Target at Citigroup - MarketBeat
Cardinal Health Earnings: Can Perfection Get Priced In Twice? - MarketBeat
CAH Maintained by Evercore ISI Group -- Price Target Raised to $270 - GuruFocus
Cardinal Health Q4 Results: EPS beats by 20%, sales miss estimates - scanx.trade
Barclays Adjusts Cardinal Health Price Target to $275 From $258, Maintains Overweight Rating - marketscreener.com
Cardinal Health (NYSE:CAH) Cash Strength Faces A Valuation Test - Kalkine Media
Cardinal Health, Lumentum Holdings, Public Storage - TradingView
Evercore ISI Adjusts PT on Cardinal Health to $265 From $270, Maintains Outperform Rating - marketscreener.com
CAH Q4 Earnings Call Centers on Fiscal 2027 Growth Outlook - TradingView
UBS Adjusts Price Target on Cardinal Health to $280 From $274, Keeps Buy Rating - marketscreener.com
Keurig Dr Pepper Adds Cardinal Health CFO Aaron Alt to Board - citybiz
Wells Fargo & Company Forecasts Strong Price Appreciation for Cardinal Health (NYSE:CAH) Stock - MarketBeat
Robert W. Baird Raises Cardinal Health (NYSE:CAH) Price Target to $274.00 - MarketBeat
Wells Fargo Adjusts Cardinal Health Price Target to $277 From $245, Maintains Overweight Rating - marketscreener.com
Mizuho Securities Adjusts Cardinal Health PT to $250 From $240, Maintains Outperform Rating - marketscreener.com
Baird Adjusts Cardinal Health Price Target to $274 From $251, Maintains Outperform Rating - marketscreener.com
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):